| Subject: | FDA Announces Safety Review of GnRH Agonists Used to Treat Prostate Cancer |
| Category: | Food and Drug Administration (FDA)
|
| Published: | Mon, 3 May 2010 - 12:00 pm |
| Audience: Urology, Oncology healthcare professionals, patients The Food and Drug Administration (FDA) is notifying healthcare professionals and patients of the FDAs preliminary and ongoing review which suggests an increase in the risk of diabetes and certain cardiovascular diseases in men treated with GnRH agonists, drugs that suppress the production of testosterone, the hormone involved in the growth of prostate cancer. Most of the studies reviewed by FDA reported small, but... The full article is available to StayAlert subscribers. Click here for a free trial subscription. |
|
RESOURCES:
External Links:
|
|
StayAlert! provides immediate online healthcare compliance validation to our healthcare users. When faced with dramatic reductions in healthcare dollars, StayAlert! focuses on those processes that can save the most time and money. By automating labor-intensive activities, StayAlert! almost instantly produces a positive impact on the healthcare user's bottom line. The policies alone included with the StayAlert! notices can save you $65,000 or more in labor costs each year. Organizations will realize dramatic cost savings through elimination of labor intensity, increased productivity with the benefit of ensuring regulatory compliance. StayAlert! is the service-oriented supplier of health care's compliance needs. StayAlert! is the only comprehensive clinical and regulatory service providing organizations in the healthcare arena with practical applications to meet complex mandated federal requirements. |
|
